On Wednesday, H.C. Wainwright maintained its Buy rating and $27.00 price target for Viridian Therapeutics (NASDAQ:VRDN), following the company's announcement of positive results from its THRIVE-1 study. Viridian Therapeutics reported on September 10 that its drug VRDN-001 showed promising results in treating thyroid eye disease (TED), potentially outperforming the current leading treatment, Tepezza, in certain measures.
The THRIVE-1 study met its primary endpoint, with 70% of patients in the treatment group exhibiting a significant reduction in proptosis, a common TED symptom, compared to only 5% in the placebo group at week 15. The mean change in proptosis for the treatment group was -2.89mm, compared to -0.48mm in the placebo group, indicating a -2.4 difference versus placebo. This result slightly exceeds the -2.3 placebo-adjusted difference reported for Tepezza.
Additionally, the study highlighted a quick response to the treatment, with a 53% proptosis responder rate by week 3 after just one infusion. This is noteworthy considering VRDN-001's shorter dosing schedule of five infusions, compared to Tepezza's eight.
Approximately 54% of patients treated with VRDN-001 achieved complete resolution of diplopia, or double vision, within 15 weeks, compared to 12% in the placebo group. Furthermore, 64% of patients reached a Clinical Activity Score (CAS) of 0 or 1 after 15 weeks, indicating minimal disease activity, in contrast to 18% in the placebo group.
The positive data from the THRIVE-1 trial suggests that VRDN-001 has the potential to offer an effective and possibly superior treatment option for patients with active TED. The rapid improvement observed in patients, coupled with a favorable safety profile, underpins the analyst's reiterated Buy rating and $27 price target for Viridian Therapeutics' shares.
In other recent news, Viridian Therapeutics has been making significant strides with its Phase III THRIVE study, showing promising results for its drug candidate, veligrotug, in treating thyroid eye disease. The study's findings were in line with expectations, with some outcomes surpassing base case predictions. B.Riley has subsequently increased its price target for Viridian to $22.00, maintaining a neutral rating.
Other financial services firms, including Stifel and BTIG, have also increased their price targets reflecting confidence in the company's ongoing trials.
Furthermore, Viridian Therapeutics has initiated a public offering of $150 million of its common stock and Series B non-voting convertible preferred stock. The proceeds from this offering will be used for clinical development programs, working capital, and general corporate purposes. The offering is managed by Jefferies, Goldman Sachs (NYSE:GS) & Co. LLC, Stifel, and RBC Capital Markets.
These are the recent developments in the company's ongoing efforts.
InvestingPro Insights
As Viridian Therapeutics (NASDAQ:VRDN) continues to make headlines with its promising clinical trials, investors are closely monitoring the company's financial health and market performance. According to InvestingPro data, Viridian has a market capitalization of $1.2 billion, reflecting investor optimism about its future prospects despite the company's current financial metrics showing a challenging landscape.
InvestingPro Tips highlight that Viridian holds more cash than debt on its balance sheet, which is an encouraging sign for the company's financial stability. This can provide the company with the flexibility to fund ongoing clinical trials and support its operational needs without the immediate pressure of debt repayment. Additionally, Viridian's liquid assets exceed its short-term obligations, further underscoring its ability to meet short-term financial commitments.
However, it's worth noting that analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company to be profitable this year. This is consistent with the adjusted P/E ratio for the last twelve months as of Q2 2024, which stands at -5.25, indicating that the company is not generating positive earnings at the moment. Moreover, the gross profit margin for the same period is significantly negative, at -57,041.32%, reflecting the high costs relative to the company's revenue.
Despite these financial challenges, the stock has experienced a significant return over the last week, with a 26.35% price total return, which may capture the investor sentiment around the recent positive news from the clinical trials. For those interested in deeper analysis, there are additional InvestingPro Tips available on the platform, providing further insights into Viridian's financials and market performance.
For more detailed analysis and tips, investors can refer to InvestingPro for a comprehensive view of Viridian Therapeutics' financial health and market standing, including the additional tips not covered here.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.